Barri, Mark Zian P.
HRN: 22-57-56 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/05/2023
OXACILLIN 500MG (VIAL)
02/05/2023
02/12/2023
IV
45mg
Q6 Hours
Seborrheic Dermatitis With Bacterial Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes